A multicentre randomised, double-blind, placebo-controlled, dose-ranging study to evaluate once daily doses of AIT-082 over 24 weeks in probable Alzheimer's disease patients. Protocol #082-99-006. (2000-2001)
Experts
Professor
Gerard Byrne
Mayne Professor of Psychiatry
Medical School
Faculty of Health, Medicine and Behavioural Sciences
